Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,512,028
  • Shares Outstanding, K 696,831
  • Annual Sales, $ 620 K
  • Annual Income, $ -583,200 K
  • EBIT $ -359 M
  • EBITDA $ -299 M
  • 60-Month Beta 0.99
  • Price/Sales 5,713.57
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 89.06% ( -4.29%)
  • Historical Volatility 121.55%
  • IV Percentile 27%
  • IV Rank 18.83%
  • IV High 416.96% on 04/25/24
  • IV Low 12.98% on 09/10/24
  • Put/Call Vol Ratio 0.56
  • Today's Volume 3,124
  • Volume Avg (30-Day) 5,626
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 173,808
  • Open Int (30-Day) 194,280

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.34
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.43 +13.77%
on 11/15/24
6.08 -17.10%
on 10/30/24
-0.57 (-10.16%)
since 10/29/24
3-Month
3.19 +57.80%
on 10/11/24
7.48 -32.62%
on 10/25/24
+1.24 (+32.63%)
since 08/29/24
52-Week
3.10 +62.58%
on 12/11/23
10.53 -52.14%
on 04/29/24
+1.06 (+26.63%)
since 11/29/23

Most Recent Stories

More News
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.9302 (+0.02%)
IOVA : 9.32 (-0.85%)
SNDX : 16.72 (+1.27%)
ONC.TO : 1.32 (-4.35%)
IBRX : 5.04 (-1.18%)
SWTX : 41.48 (-0.60%)
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

ONCY : 0.9302 (+0.02%)
IOVA : 9.32 (-0.85%)
SNDX : 16.72 (+1.27%)
ONC.TO : 1.32 (-4.35%)
IBRX : 5.04 (-1.18%)
SWTX : 41.48 (-0.60%)
ImmunityBio: Q3 Earnings Snapshot

ImmunityBio: Q3 Earnings Snapshot

IBRX : 5.04 (-1.18%)
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published...

BIOV.CN : 0.0600 (unch)
BVAXF : 0.0503 (+11.78%)
BNTX : 118.39 (-1.93%)
CVAC : 2.87 (unch)
VXRT : 0.6022 (-1.28%)
IBRX : 5.04 (-1.18%)
ImmunityBio: Q2 Earnings Snapshot

ImmunityBio: Q2 Earnings Snapshot

IBRX : 5.04 (-1.18%)
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050

/CNW/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...

BIOV.CN : 0.0600 (unch)
BVAXF : 0.0503 (+11.78%)
MRNA : 43.06 (-0.76%)
BOLD : 2.73 (+8.33%)
IBRX : 5.04 (-1.18%)
MGNX : 3.59 (-1.37%)
Promising Outlook as Biotech Sector Advances Cancer Treatments Amidst Rising Diagnoses

USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society...

BRX : 30.07 (-0.99%)
BIOV.CN : 0.0600 (unch)
BVAXF : 0.0503 (+11.78%)
MRNA : 43.06 (-0.76%)
BOLD : 2.73 (+8.33%)
IBRX : 5.04 (-1.18%)
MGNX : 3.59 (-1.37%)
Biotech Sector Advances in Pancreatic Cancer Research

USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...

BRX : 30.07 (-0.99%)
ONCY : 0.9302 (+0.02%)
ONC.TO : 1.32 (-4.35%)
NVS : 105.77 (+0.86%)
IBRX : 5.04 (-1.18%)
ACRS : 4.07 (+6.54%)
NUVB : 2.90 (+0.35%)
Biotech’s Role in Addressing the Pancreatic Cancer Emergency

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END

NVX : 1.9801 (+0.01%)
ONCY : 0.9302 (+0.02%)
ONC.TO : 1.32 (-4.35%)
NVS : 105.77 (+0.86%)
IBRX : 5.04 (-1.18%)
ACRS : 4.07 (+6.54%)
NUVB : 2.90 (+0.35%)
Should You Still Buy the Nasdaq's Best-Performing October Stocks?

Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.

COMP : 7.09 (-1.53%)
GPCR : 33.15 (-1.78%)
IBRX : 5.04 (-1.18%)
OLK : 26.08 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 5.27
2nd Resistance Point 5.22
1st Resistance Point 5.13
Last Price 5.04
1st Support Level 4.98
2nd Support Level 4.93
3rd Support Level 4.84

See More

52-Week High 10.53
Fibonacci 61.8% 7.69
Fibonacci 50% 6.81
Fibonacci 38.2% 5.94
Last Price 5.04
52-Week Low 3.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar